# Regenacy Pharmaceuticals, Inc.

> Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral, isoform-selective histone deacetylase (HDAC) inhibitors to restore normal protein function. Spun out in 2016 from the assets of Acetylon Pharmaceuticals after Celgene's acquisition, Regenacy's lead drug ricolinostat (ACY-1215) is a selective HDAC6 inhibitor in clinical development for painful diabetic peripheral neuropathy and other peripheral neuropathies, with an additional portfolio of HDAC1,2 inhibitors targeting blood diseases and cognitive disorders.

- **Founded:** 2016
- **Headquarters:** Waltham, Massachusetts, United States
- **Founders:** Simon S. Jones, Ph.D. (President & CEO (appointed 2017); long-time HDAC research lead, formerly at Acetylon Pharmaceuticals from 2009)
- **Team size:** Small (~5 employees reported); lean clinical-stage operation
- **Products:** Ricolinostat (ACY-1215), Selective HDAC1,2 inhibitors
- **Notable:** Spun out of Acetylon Pharmaceuticals in 2016, securing rights to ricolinostat for non-cancer indications after Celgene's acquisition., Raised $48.6M total across Series A and B rounds., Advanced ricolinostat into a Phase 2 trial for painful diabetic peripheral neuropathy and completed enrollment in 2022.

## Products & services

- **Ricolinostat (ACY-1215)** — An orally bioavailable, first-in-class selective inhibitor of HDAC6, a microtubule-modifying enzyme. Designed to restore normal intracellular protein and organelle transport in nerves; in clinical development for painful diabetic peripheral neuropathy (DPN), with potential in chemotherapy-induced peripheral neuropathy (CIPN) and Charcot-Marie-Tooth type 2 (CMT2).
- **Selective HDAC1,2 inhibitors** — A proprietary portfolio of isoform-selective HDAC1 and HDAC2 inhibitors with potential to treat blood diseases (leukemia, sickle cell disease, beta-thalassemia) and cognitive dysfunction in neurological disorders such as Alzheimer's disease.

## Achievements

- Spun out of Acetylon Pharmaceuticals in 2016, securing rights to ricolinostat for non-cancer indications after Celgene's acquisition.
- Raised $48.6M total across Series A and B rounds.
- Advanced ricolinostat into a Phase 2 trial for painful diabetic peripheral neuropathy and completed enrollment in 2022.
- Presented preclinical data showing HDAC1,2 inhibition improved cognitive function in Alzheimer's mouse models at the Alzheimer's Association International Conference (2017).
- Secured patent issuance for ricolinostat in diabetic peripheral neuropathy.
- Established a China joint venture with 3E Bioventures to develop ricolinostat regionally.

## Latest updates

- **2022-08** — Completed enrollment of Phase 2 study of ricolinostat in painful diabetic peripheral neuropathy and closed a $9.3M Series B financing.
- **2020-12** — Formed a joint venture with 3E Bioventures to develop ricolinostat in China and initiated a U.S. Phase 2 study in painful diabetic peripheral neuropathy.
- **2020-03** — Raised $30M Series A co-led by Cobro Ventures and Taiwania Capital Management.

## Links

- Website: https://regenacy.com
- LinkedIn: https://www.linkedin.com/company/regenacy-pharmaceuticals

---

Profile page: https://yespress.io/regenacy-pharmaceuticals-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-08